Outcomes of GLP-1 receptor agonist use in early pregnancy

Investigators examined whether glucagon-like peptide-1 receptor agonists may be safe and effective if continued during the first trimester of pregnancy.

In a study published in the Annals of Internal Medicine, the investigators used 2011 to 2024 insurance claims data to analyze the incidence of nonlive birth, abnormal fetal growth and nonchromosomal major congenital malformation among more than 3,500 pregnant women aged 16 to 55 years with Type 2 diabetes who either continued or did not continue GLP-1 receptor agonist use during the first trimester.

Although there were slight increases in risk among those who continued GLP-1 receptor agonists, the investigators noted that there were no statistically significant differences in the likelihood of nonlive birth, small or large for gestational age, and major congenital malformation between the GLP-1 receptor agonist continuation and discontinuation groups.

However, because the data for small for gestational age and major congenital malformation was mixed, further studies will be needed to confirm whether GLP-1 receptor agonists are safe in early pregnancy among patients with Type 2 diabetes.

Read more: Annals of Internal Medicine

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.